ImmunoGen Inc. (Nasdaq: IMGN) reported upbeat from an ongoing Phase 1 trial
of FRa-targeting antibody conjugate mirvetuximab soravtansine sending the stock price soaring $5.68 to $14.66.
ImmunoGen reports upbeat ongoing results
June 01, 2015 at 13:48 PM EDT
